Arcus Biosciences Inc reports results for the quarter ended in September 30 - Earnings Summary

Arcus Biosciences

07/11/2024 15:08

* Arcus Biosciences Inc  RCUS.N  reported a quarterly
adjusted
loss of 100 cents​​ per share for the quarter ended September
30, lower than the same quarter last year, when the company
reported EPS of -94 cents.  The mean expectation of
twelve analysts for the quarter was for a loss of $1.06 per
share. Wall Street expected results to range from $-1.38 to -85
cents per share.
    * Revenue rose 50% to $48.00 million from a year ago;
analysts
expected $37.56 million. 
    * Arcus Biosciences Inc's reported EPS for the quarter was a
loss
of $1.00​.
    * The company reported a quarterly loss of $92 million.
    * Arcus Biosciences Inc shares had risen by 2.9% this
quarter and
lost 17.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 25%
in the last three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Arcus Biosciences
Inc is $35.00 
This summary was machine generated from LSEG data November 7 at
03:08 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -1.06          -1.00          Beat
 Jun. 30 2024      -1.10          -1.02          Beat
 Mar. 31 2024      -0.95          -0.05          Beat
 Dec. 31 2023      -1.02          -1.08          Missed